Site-specific nitration of apolipoprotein a-i at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional

Journal of Biological Chemistry

Volumn 289, Issue 15, 2014, Pages 10276-10292

  DiDonato, Joseph A ^a   Aulak, Kulwant ^a   Huang, Ying ^a   Wagner, Matthew ^a   Gerstenecker, Gary ^a,b   Topbas, Celalettin ^a,b   Gogonea, Valentin ^a,b   DiDonato, Anthony J ^a,c   Tang, W H Wilson ^a   Mehl, Ryan A ^d   Fox, Paul L ^a   Plow, Edward F ^a,e   Smith, Jonathan D ^a   Fisher, Edward A ^a   Hazen, Stanley L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND STATE UNIVERSITY   (United States)

^c JOHN CARROLL UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; MONOCLONAL ANTIBODIES; NITROGEN OXIDES; RECOVERY; TRANSPORT PROPERTIES;

APOLIPOPROTEIN A-I (APOA-I); ATHEROSCLEROTIC LESIONS; HUMAN ATHEROSCLEROTIC PLAQUES; HUMAN CORONARY ARTERIES; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; POST-TRANSLATIONAL MODIFICATIONS; ULTRACENTRIFUGATION ANALYSIS; UNNATURAL AMINO ACIDS;

NITRATION;

APOLIPOPROTEIN A1; CHOLESTEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4G11.2; TYROSINE; UNCLASSIFIED DRUG;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; DISEASE ASSOCIATION; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOLECULAR MECHANICS; MOUSE; NITRATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION;

AMINOACYL-TRNA SYNTHETASE; APOLIPOPROTEINS; ATHEROSCLEROSIS; DYSFUNCTIONAL HDL; NITROTYROSINE; ORTHOGONAL AMINO ACID; PEROXIDASE; POST-TRANSLATIONAL MODIFICATION; PROTEIN NITRATION; UNNATURAL AMINO ACID (UAA);

ANIMALS; ANTIBODIES, MONOCLONAL; AORTA; APOLIPOPROTEIN A-I; CORONARY VESSELS; ESCHERICHIA COLI; HUMANS; MALE; MICE; MICE, INBRED BALB C; PEROXIDASES; PLAQUE, ATHEROSCLEROTIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; REACTIVE NITROGEN SPECIES; RECOMBINANT PROTEINS; TYROSINE; ULTRACENTRIFUGATION;

EID: 84898627368     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.556506     Document Type: Article

References (59)

1. Hazen, S. L., and Heinecke, J. W. (1997) 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Investig. 99, 2075-2081
2. Souza, J. M., Daikhin, E., Yudkoff, M., Raman, C. S., and Ischiropoulos, H. (1999) Factors determining the selectivity of protein tyrosine nitration. Arch. Biochem. Biophys. 371, 169-178
3. Viera, L., Ye, Y. Z., Estévez, A. G., and Beckman, J. S. (1999) Immunohistochemical methods to detect nitrotyrosine. Methods Enzymol. 301, 373-381
4. Wu, W., Samoszuk, M. K., Comhair, S. A., Thomassen, M. J., Farver, C. F., Dweik, R. A., Kavuru, M. S., Erzurum, S. C., and Hazen, S. L. (2000) Eosinophils generate brominating oxidants in allergen-induced asthma. J. Clin. Investig. 105, 1455-1463
5. Brennan, M. L., Wu, W., Fu, X., Shen, Z., Song, W., Frost, H., Vadseth, C., Narine, L., Lenkiewicz, E., Borchers, M. T., Lusis, A. J., Lee, J. J., Lee, N. A., Abu-Soud, H. M., Ischiropoulos, H., and Hazen, S. L. (2002) A tale of two controversies: defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J. Biol. Chem. 277, 17415-17427
6. Pennathur, S., Bergt, C., Shao, B., Byun, J., Kassim, S. Y., Singh, P., Green, P. S., McDonald, T. O., Brunzell, J., Chait, A., Oram, J. F., O'brien, K., Geary, R. L., and Heinecke, J. W. (2004) Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J. Biol. Chem. 279, 42977-42983
7. Zheng, L., Nukuna, B., Brennan, M. L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., Ischiropoulos, H., Smith, J. D., Kinter, M., and Hazen, S. L. (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Investig. 114, 529-541
8. Zheng, L., Settle, M., Brubaker, G., Schmitt, D., Hazen, S. L., Smith, J. D., and Kinter, M. (2005) Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J. Biol. Chem. 280, 38-47
9. Peng, D.-Q., Wu, Z., Brubaker, G., Zheng, L., Settle, M., Gross, E., Kinter, M., Hazen, S. L., and Smith, J. D. (2005) Tyrosine modification is not required for myeloperoxidase-induced loss of apolipoprotein A-I functional activities. J. Biol. Chem. 280, 33775-33784
10. Wang, Z., Nicholls, S. J., Rodriguez, E. R., Kummu, O., Hörkkö, S., Barnard, J., Reynolds, W. F., Topol, E. J., DiDonato, J. A., and Hazen, S. L. (2007) Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat. Med. 13, 1176-1184
11. Vaisar, T., Shao, B., Green, P. S., Oda, M. N., Oram, J. F., and Heinecke, J. W. (2007) Myeloperoxidase and inflammatory proteins: pathways for generating dysfunctional high-density lipoprotein in humans. Curr. Atheroscler. Rep. 9, 417-424
12. Wu, Z., Wagner, M. A., Zheng, L., Parks, J. S., Shy, J. M., 3rd, Smith, J. D., Gogonea, V., and Hazen, S. L. (2007) The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat. Struct. Mol. Biol. 14, 861-868
13. Peng, D.-Q., Brubaker, G., Wu, Z., Zheng, L., Willard, B., Kinter, M., Hazen, S. L., and Smith, J. D. (2008) Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function. Arterioscler. Thromb. Vasc. Biol. 28, 2063-2070
14. Young, T. S., and Schultz, P. G. (2010) Beyond the canonical 20 amino acids: expanding the genetic lexicon. J. Biol. Chem. 285, 11039-11044
15. Samuelson, J. C., Singh-Blom, A., Hughes, R., and Ellington, A. (2013) in Enzyme Engineering, pp. 93-114, Humana Press, Totowa, NJ
16. Franco, M. C., Ye, Y., Refakis, C. A., Feldman, J. L., Stokes, A. L., Basso, M., Melero Fernández de Mera, R. M., Sparrow, N. A., Calingasan, N. Y., Kiaei, M., Rhoads, T. W., Ma, T. C., Grumet, M., Barnes, S., Beal, M. F., Beckman, J. S., Mehl, R., and Estévez, A. G. (2013) Nitration of Hsp90 induces cell death. Proc. Natl. Acad. Sci. U.S.A. 110, E1102-E1111
17. Neumann, H., Hazen, J. L., Weinstein, J., Mehl, R. A., and Chin, J. W. (2008) Genetically encoding protein oxidative damage. J. Am. Chem. Soc. 130, 4028-4033
18. Undurti, A., Huang, Y., Lupica, J. A., Smith, J. D., DiDonato, J. A., and Hazen, S. L. (2009) Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J. Biol. Chem. 284, 30825-30835
19. Bergt, C., Pennathur, S., Fu, X., Byun, J., O'Brien, K., McDonald, T. O., Singh, P., Anantharamaiah, G. M., Chait, A., Brunzell, J., Geary, R. L., Oram, J. F., and Heinecke, J. W. (2004) The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc. Natl. Acad. Sci. U.S.A. 101, 13032-13037
20. Hadfield, K. A., Pattison, D. I., Brown, B. E., Hou, L., Rye, K. A., Davies, M. J., and Hawkins, C. L. (2013) Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl). Biochem. J. 449, 531-542
21. Shao, B., Bergt, C., Fu, X., Green, P., Voss, J. C., Oda, M. N., Oram, J. F., and Heinecke, J. W. (2005) Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J. Biol. Chem. 280, 5983-5993
22. Shao, B., Pennathur, S., and Heinecke, J. W. (2012) Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J. Biol. Chem. 287, 6375-6386
23. Wu, Z., Gogonea, V., Lee, X., Wagner, M. A., Li, X. M., Huang, Y., Undurti, A., May, R. P., Haertlein, M., Moulin, M., Gutsche, I., Zaccai, G., Didonato, J. A., and Hazen, S. L. (2009) Double superhelix model of high density lipoprotein. J. Biol. Chem. 284, 36605-36619
24. Stahlman, M., Davidsson, P., Kanmert, I., Rosengren, B., Borén, J., Fagerberg, B., and Camejo, G. (2008) Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J. Lipid Res. 49, 481-490
25. Markwell, M. A., Haas, S. M., Bieber, L. L., and Tolbert, N. E. (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem. 87, 206-210
26. Parks, J. S., Gebre, A. K., and Furbee, J. W. (1999) Lecithin-cholesterol acyltransferase. Assay of cholesterol esterification and phospholipase A2 activities. Methods Mol. Biol. 109, 123-131
27. Li, X. M., Tang, W. H., Mosior, M. K., Huang, Y., Wu, Y., Matter, W., Gao, V., Schmitt, D., Didonato, J. A., Fisher, E. A., Smith, J. D., and Hazen, S. L. (2013) Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler. Thromb. Vasc. Biol. 33, 1696-1705
28. Matz, C. E., and Jonas, A. (1982) Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J. Biol. Chem. 257, 4535-4540
29. Rakita, R. M., Michel, B. R., and Rosen, H. (1990) Differential inactivation of Escherichia coli membrane dehydrogenases by a myeloperoxidase-mediated antimicrobial system. Biochemistry 29, 1075-1080
30. Morita, Y., Iwamoto, H., Aibara, S., Kobayashi, T., and Hasegawa, E. (1986) Crystallization and properties of myeloperoxidase from normal human leukocytes. J. Biochem. 99, 761-770
31. Nelson, D. P., and Kiesow, L. A. (1972) Enthalpy of decomposition of hydrogen peroxide by catalase at 25 degrees C (with molar extinction coefficients of H2O2 solutions in the UV). Anal. Biochem. 49, 474-478
32. Morris, J. C. (1966) The acid ionization constant of HOCl from 5 to 35°. J. Phys. Chem. 70, 3798-3805
33. Reiter, C. D., Teng, R. J., and Beckman, J. S. (2000) Superoxide reacts with nitric oxide to nitrate tyrosine at physiological pH via peroxynitrite. J. Biol. Chem. 275, 32460-32466
34. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685
35. Wang, L., Brock, A., Herberich, B., and Schultz, P. G. (2001) Expanding the genetic code of Escherichia coli. Science 292, 498-500
36. Beckman, J. S., and Koppenol, W. H. (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. Cell Physiol. 271, C1424-C1437
37. Boullier, A., Bird, D. A., Chang, M. K., Dennis, E. A., Friedman, P., Gillotre- Taylor, K., Hörkkö, S., Palinski, W., Quehenberger, O., Shaw, P., Steinberg, D., Terpstra, V., and Witztum, J. L. (2001) Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. N.Y. Acad. Sci. 947, 214-222; discussion 222-223
38. Lusis, A. J. (2000) Atherosclerosis. Nature 407, 233-241
39. Navab, M., Hama, S. Y., Reddy, S. T., Ng, C. J., Van Lenten, B. J., Laks, H., and Fogelman, A. M. (2002) Oxidized lipids as mediators of coronary heart disease. Curr. Opin. Lipidol. 13, 363-372
40. Shishehbor, M. H., Aviles, R. J., Brennan, M. L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F., Jr., Penn, M. S., Sprecher, D. L., Vita, J. A., and Hazen, S. L. (2003) Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289, 1675-1680
41. Brennan, M. L., Penn, M. S., Van Lente, F., Nambi, V., Shishehbor, M. H., Aviles, R. J., Goormastic, M., Pepoy, M. L., McErlean, E. S., Topol, E. J., Nissen, S. E., and Hazen, S. L. (2003) Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349, 1595-1604
42. Libby, P. (2012) Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32, 2045-2051
43. Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., and Dawber, T. R. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am. J. Med. 62, 707-714
44. Badimon, J. J., Badimon, L., Galvez, A., Dische, R., and Fuster, V. (1989) High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab. Invest. 60, 455-461
45. Badimon, J. J., Badimon, L., and Fuster, V. (1990) Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterolfed rabbit. J. Clin. Investig. 85, 1234-1241
46. Nissen, S. E., Tardif, J. C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., Tuzcu, E. M., and ILLUSTRATE Investigators (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304-1316
47. Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., and Brewer, B., and ILLUMINATE Investigators (2007) Effects of torcetrapib in patients at high risk for coronary events. New Engl. J. Med. 357, 2109-2122
48. AIM-HIGH Investigators, Boden, W. E., Probstfield, J. L., Anderson, T., Chaitman, B. R., Desvignes-Nickens, P., Koprowicz, K., McBride, R., Teo, K., and Weintraub, W. (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267
49. Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G., and Clift, S. M. (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353, 265-267
50. Plump, A. S., Scott, C. J., and Breslow, J. L. (1994) Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U.S.A. 91, 9607-9611
51. Hughes, S. D., Verstuyft, J., and Rubin, E. M. (1997) HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17, 1725-1729
52. Hewing, B., Parathath, S., Barrett, T., Kellie Chung, W. K., Astudillo, Y. M., Hamada, T., Ramkhelawon, B., Tallant, T. C., Yusufishaq, M. S., Didonato, J. A., Huang, Y., Buffa, J., Berisha, S. Z., Smith, J. D., Hazen, S. L., and Fisher, E. A. (2014) Effects of native and myeloperoxidase-modified apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 10.1161/ATVBAHA.113.303044
53. Kinlay, S., Libby, P., and Ganz, P. (2001) Endothelial function and coronary artery disease. Curr. Opin. Lipidol 12, 383-389
54. Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., Halpern, S., Crowe, T., Blankenship, J. C., and Kerensky, R. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292-2300
55. Tardif, J. C., Grégoire, J., L'Allier, P. L., Ibrahim, R., Lespérance, J., Heinonen, T. M., Kouz, S., Berry, C., Basser, R., Lavoie, M. A., Guertin, M. C., Rodés-Cabau, J., and Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297, 1675-1682
56. Sacks, F. M., Rudel, L. L., Conner, A., Akeefe, H., Kostner, G., Baki, T., Rothblat, G., de la Llera-Moya, M., Asztalos, B., Perlman, T., Zheng, C., Alaupovic, P., Maltais, J. A., and Brewer, H. B. (2009) Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J. Lipid Res. 50, 894-907
57. Feig, J. E., Hewing, B., Smith, J. D., Hazen, S. L., and Fisher, E. A. (2014) High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies. Circ. Res. 114, 205-213
58. DiDonato, J. A., Huang, Y., Aulak, K. S., Even-Or, O., Gerstenecker, G., Gogonea, V., Wu, Y., Fox, P. L., Tang, W. H., Plow, E. F., Smith, J. D., Fisher, E. A., and Hazen, S. L. (2013) Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation 128, 1644-1655
59. Huang, Y., Didonato, J. A., Levison, B. S., Schmitt, D., Li, L., Wu, Y., Buffa, J., Kim, T., Gerstenecker, G. S., Gu, X., Kadiyala, C. S., Wang, Z., Culley, M. K., Hazen, J. E., Didonato, A. J., Fu, X., Berisha, S. Z., Peng, D., Nguyen, T. T., Liang, S., Chuang, C. C., Cho, L., Plow, E. F., Fox, P. L., Gogonea, V., Tang, W. H., Parks, J. S., Fisher, E. A., Smith, J. D., and Hazen, S. L. (2014) An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. 20, 193-203